Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Monopar Advances ALXN1840 NDA Submission and Reports Q1 2026 Financials

Monopar Therapeutics announced its first quarter 2026 financial results and provided key business updates. The company is on track to submit a New Drug Application (NDA) for ALXN1840 (tiomolibdate choline) for Wilson disease to the U.S. FDA in mid-2026, following positive Phase 3 FoCus trial data presented at recent medical conferences. Financially, Monopar reported $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, projecting these funds to support operations through at least December 31, 2027. The net loss for Q1 2026 was $3.9 million, an increase from $2.6 million in Q1 2025, primarily due to higher R&D and G&A expenses.

• Monopar Therapeutics is progressing with its New Drug Application (NDA) submission for ALXN1840 (tiomolibdate choline) for Wilson disease, targeting mid-2026 with the U.S. FDA. This follows compelling data from the randomized controlled Phase 3 FoCus trial, which demonstrated greater neurologic benefit compared to standard of care in patients with neurologic symptoms. These findings were recently highlighted in presentations at the American Academy of Neurology (AAN) Annual Meeting 2026, the European Academy of Neurology (EAN) 2026, and the European Association for the Study of the Liver (EASL) Congress 2026, underscoring the drug's potential.
• As of March 31, 2026, Monopar Therapeutics maintained a robust financial position with $137.5 million in cash, cash equivalents, and investments. The company anticipates that these funds will adequately support its operational needs, including regulatory and potential commercial activities for ALXN1840, ongoing development of MNPR-101 programs, and internal research and development initiatives, through at least December 31, 2027. This financial stability was bolstered by approximately $91.9 million in net proceeds from a capital raise conducted in September 2025.
• For the first quarter ended March 31, 2026, Monopar Therapeutics reported a net loss of $3.9 million, or $0.46 per share, an increase from a net loss of $2.6 million, or $0.38 per share, in the corresponding period of 2025. This rise in net loss was primarily driven by a significant increase in Research and Development (R&D) expenses, which grew by $1.8 million to $3.5 million, and a modest increase in General and Administrative (G&A) expenses. Conversely, interest income saw a substantial increase, reaching $1.3 million, due to higher bank balances and investments in U.S. Treasury securities.

ALXN1840's Neurologic Benefit Over Standard of Care in Wilson Disease

Published studies demonstrate that investigational therapies for Wilson disease offer distinct advantages over standard-of-care treatments, particularly for patients with neurologic presentations. Tetrathiomolybdate, the most studied investigational therapy, is specifically recommended for initial treatment of patients presenting with neurologic or psychiatric symptoms, while standard treatments like zinc and trientine are primarily used for hepatic presentations and maintenance therapy. This therapeutic differentiation reflects tetrathiomolybdate's ability to provide rapid, safe control of copper by forming a tripartite complex with copper and protein, effectively blocking copper absorption from the intestine or rendering blood copper non-toxic. In contrast, neurologic patients face significant risk of serious permanent neurological worsening with penicillamine, while zinc is considered too slow-acting for optimal initial neurologic treatment.

Comparative studies reveal important differences in treatment outcomes across therapeutic approaches. A cross-combination chelation approach using intravenous DMPS (sodium 2,3-dimercapto-1-propane sulfonate) alternately with oral penicillamine plus zinc demonstrated promising results in 35 patients, with improved or recovered liver function in 71% of patients and alleviated neurologic symptoms in 50% during 6 months to 5 years follow-up. However, adverse effects included neutropenia, thrombocytopenia, allergic reactions, and bleeding tendency. Standard-of-care treatments show variable outcomes, with both D-penicillamine and trientine producing comparable results overall—hepatic improvements in more than 90% of therapy-naive patients and neurologic improvements in more than 55%—though trientine demonstrates fewer adverse events leading to discontinuation.

The evidence base for comparing these therapies remains limited, with no randomized controlled trials of optimal design conducted in Wilson disease, making it impossible to assign high or moderate quality evidence to treatment recommendations. Most evaluations are based on large case series and observational studies that are heterogeneous and generally of low validity. Despite these limitations, current data suggest that treatment selection should be individualized based on disease presentation and stage, with investigational therapies like tetrathiomolybdate filling a critical therapeutic niche for neurologic presentations where standard treatments may be inadequate or carry excessive risk of neurological deterioration.

Addressing Persistent Unmet Needs in Wilson Disease Treatment

Current treatment approaches for Wilson disease face significant challenges that impact both diagnostic accuracy and therapeutic outcomes. These limitations span from initial disease recognition through long-term management, creating barriers to optimal patient care. Additionally, existing therapeutic options have notable efficacy and safety constraints that necessitate improved treatment strategies.

• Diagnostic delays and misrecognition: Up to two-thirds of cases are initially misdiagnosed, with mean diagnostic delays of 2 years in Indian populations and 27.5 ± 41.9 months in Brazilian cohorts, increasing the risk of permanent liver and brain damage

• Protean clinical manifestations: The myriad nonspecific symptoms and multisystem involvement mimic other neurologic, psychiatric, and hematologic disorders, making diagnosis dependent on high clinical suspicion

• Penicillamine-associated adverse effects: This first-line chelator causes worsening of neurological symptoms and serious permanent neurological deterioration, particularly in patients presenting with neurological disease

• Suboptimal therapeutic options for neurological presentations: Zinc therapy is too slow-acting for initial neurological treatment, while penicillamine carries high risk of neurological worsening in this vulnerable population

• Lack of standardized treatment protocols: Significant variability exists in initial therapies among California and European providers, with inconsistent management approaches even among North American and European society guidelines

• Limited high-quality evidence base: Scarcity of randomized controlled trials hampers evidence-based treatment decisions, despite widespread use of combination chelator-zinc therapies requiring further exploration

• Medication adherence and monitoring challenges: Persistent problems with treatment compliance and follow-up evaluation compromise long-term therapeutic success

• Combination therapy safety concerns: Penicillamine plus zinc sulfate combinations demonstrate significantly higher mortality rates compared to other combination approaches (16.3% vs. 4.7%; RR: 3.51, 95% CI 1.54-8.00)

ALXN1840's Potential to Reshape the Wilson Disease Landscape

The Wilson disease treatment landscape has undergone significant evolution over the past five years, marked by regulatory approvals of new formulations and emerging real-world evidence that highlights persistent treatment gaps. The most notable development was the FDA approval of trientine tetrahydrochloride (TETA-4HCl, Cuvrior) on April 28, 2022, for adult patients with Wilson disease who are de-coppered and tolerant to D-penicillamine. This formulation represents the only trientine variant compared with D-penicillamine in a prospective randomized clinical trial, demonstrating non-inferiority to D-penicillamine in adults with stable Wilson disease. The drug has subsequently received approval across multiple international jurisdictions including the European Union, UK, and several other countries for adults and children aged 5 years or more who are intolerant to D-penicillamine.

Real-world evidence from recent studies reveals concerning treatment patterns and outcomes that underscore substantial unmet medical needs in Wilson disease management. US claims database analysis (2016-2021) demonstrated that only 15.1% of 5,376 patients with Wilson disease diagnostic codes had documented specific treatment, with patients showing excess early mortality compared to the general American population (standardized mortality ratio: 2.19). Treatment selection patterns from 2012-2017 showed penicillamine monotherapy as the most common first-line therapy (45.5%), followed by trientine monotherapy (26.1%) and chelator/zinc combination therapy (21.2%). Notably, 75.2% of patients remained on first-line therapy during follow-up, while treatment patterns varied significantly by disease presentation, practice setting, physician specialty, and geographic location, indicating a lack of consensus regarding optimal first-line treatment approaches.

Recent clinical research has provided important insights into combination therapy risks and treatment-related neurological complications. A systematic review of 17 combination therapy studies involving 1,056 patients revealed that combination therapies were significantly less effective for hepatic patients compared to those with neurological manifestations (47.1% vs. 78.6%). Particularly concerning, penicillamine plus zinc sulfate combination resulted in significantly higher mortality rates compared to other combination therapy types (16.3% vs. 4.7%). Additionally, studies have identified distinct patterns of neurological worsening, with early treatment-associated peaks occurring within 3 months of therapy initiation (26.1% of neurological patients) and late adherence-associated peaks after 12 months of treatment. These findings emphasize the need for careful monitoring and evidence-based treatment pathways to address the persistent challenges in Wilson disease management.

ALXN1840 Poised to Redefine Neurologic Wilson Disease Treatment

The upcoming New Drug Application for ALXN1840 (tiomolibdate choline) for Wilson disease represents a significant development for patients and the pharmaceutical industry alike. For decades, managing Wilson disease, particularly in patients presenting with neurological symptoms, has been a complex challenge. Traditional chelating agents like D-penicillamine are known to worsen neurological function in a substantial percentage of patients, while zinc therapy is often too slow-acting for acute presentations, creating a critical therapeutic void.

Tiomolibdate choline, a derivative of tetrathiomolybdate (TTM), has emerged as a promising solution. Research indicates its excellent efficacy in stabilizing neurological function in these vulnerable patients, with a significantly lower incidence of neurological deterioration compared to D-penicillamine. This positions ALXN1840 to potentially become a preferred initial therapy, offering a much-needed option that prioritizes neurological stability. The mechanism of action for bis-choline tetrathiomolybdate, the likely form of ALXN1840, has recently been clarified: it primarily works by significantly reducing intestinal copper absorption and retaining copper in the bloodstream, thereby limiting its toxic accumulation in organs like the liver and brain. This refined understanding is crucial for optimizing its use and monitoring.

However, the path forward is not without considerations. Historical data on TTM highlight potential adverse effects, including bone marrow suppression and elevated aminotransferase levels, particularly with rapid dose escalation. While often manageable, their incidence and severity with ALXN1840's specific formulation will be closely scrutinized. The existing treatment landscape, though imperfect, is established, and ALXN1840 will need to clearly differentiate itself through compelling clinical outcomes and a favorable safety profile to drive widespread adoption. Monopar's strong financial position provides a solid foundation for the drug's launch and continued development, potentially extending the copper chelation platform to other indications where copper dysregulation plays a role, as suggested by earlier research. This NDA submission is not just about a new drug; it's about a potential paradigm shift in how we approach a debilitating rare disease.